

INNOVUS PHARMACEUTICALS, INC.

Form 8-K

April 01, 2019

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington D.C. 20549**

**Form 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 1, 2019**

**INNOVUS PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

000-52991 90-0814124

(Commission

File Number)

(IRS Employer Identification No.)

8845 Rehco Road, San Diego, CA

(Address of Principal Executive Offices)

92122

(Zip Code)

Registrant's telephone number, including area code: (858) 964-5123

Edgar Filing: INNOVUS PHARMACEUTICALS, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

In this report, “Innovus Pharmaceuticals,” “Innovus Pharma,” “the Company,” “we,” “us” and “our” refer to Innovus Pharmaceuticals, Inc., and/or one or more of our wholly-owned subsidiaries, unless the context otherwise provides. Innovus Pharma® is a registered service mark of Innovus Pharmaceuticals, Inc.

## **Item 2.02 – Results of Operations and Financial Condition**

On April 1, 2019, the Company issued a press release reporting our financial results for the year ended December 31, 2018. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

## **Item 9.01 – Financial Statements and Exhibits**

### **(d) Exhibits**

<b><u>Exhibit Number</u></b>	<b><u>Description</u></b>
------------------------------	---------------------------

99.1	<u>Press release issued April 1, 2019, reporting financial results for the year ended December 31, 2018</u>
------	---

## **SIGNATURES**

Pursuant to  
the  
requirements  
of the  
Securities  
Exchange  
Act of 1934,  
the  
Registrant  
has duly  
caused this  
Report to be  
signed on its  
behalf by the  
undersigned  
hereunto duly  
authorized.

Date: April 1, 2019

**INNOVUS PHARMACEUTICALS, INC.**

By: /s/ RANDY BERHOLTZ

Randy Berholtz

Executive Vice President, Corporate Development

and General Counsel

---

EXHIBIT INDEX

<u>Exhibit</u> <u>No.</u>	<u>Description</u>
------------------------------	--------------------

99.1	Press release issued April 1, 2019, reporting financial results for the year ended December 31, 2018
------	--